NEW YORK and HERZLIYA PITUACH,
Israel, Nov. 11, 2014 /PRNewswire/ -- Immune
Pharmaceuticals Inc. (NASDAQ: IMNP) announced that Dr. Daniel Teper, Chairman & CEO, will discuss
personalized medicine at a panel taking place on Thursday, November 13, 2014, at 9:45 a.m.
Dr. Teper commented: "Personalized medicine allows for
physicians to stratify patients based on biomarkers, helping
provide the right drug for the right patient. Immune is developing
Bertilimumab for the treatment of auto-immune diseases based on
tissue eotaxin-1 levels. Immune is also developing NanomAbs for the
targeted delivery of chemotherapeutics based on over-expression of
certain tumor cell membrane proteins."
Leading CEOs from New York,
Boston, California, Europe and Asia biotechnology communities will gather at
the 2014 NY/NJ CEO Biotech Conference to be held on
November 12th and 13th at Apella in New York
City. The NY/NJ CEO Biotech Conference is an off-the-record
forum for industry CEOs and decision makers in the life sciences.
About Immune Pharmaceuticals Inc.
Immune Pharmaceuticals Inc. applies a personalized approach to
treatment, developing novel, highly targeted antibody therapeutics
to improve the lives of patients with inflammatory diseases and
cancer. The Company's lead product candidate, bertilimumab,
is in clinical development for moderate to severe
ulcerative colitis and Crohn's disease as well as bullous
pemphigoid, an orphan auto-immune dermatological condition. Immune
licensed worldwide rights for systemic indications of bertilimumab
from iCo Therapeutics (TSX: ICO; OTCQX: ICOTF) in June 2011, while iCo retained rights to all
ophthalmic indications. iCo originally licensed the exclusive
world-wide rights to bertilimumab in 2006 from MedImmune, the
Global Research and Development Arm of AstraZeneca. Immune's
pipeline also includes NanomAbs®, antibody nanoparticle conjugates,
for the targeted delivery of chemotherapeutics, and AmiKet™, a
Neuropathic Pain drug candidate ready for Phase III. AmiKet has
received Orphan Drug Designation for Post Herpetic Neuralgia.
For more information, visit Immune's website at
www.immunepharmaceuticals.com, the content of which is not a part
of this press release.
Erik Penser Bankaktiebolag is engaged as Immune´s Certified
Adviser on NASDAQ OMX First North Premier.
Forward-Looking Statements
This news release and any oral statements made with respect to
the information contained in this news release contain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. You are urged to
consider statements that include the words "may," "will," "would,"
"could," "should," "believes," "estimates," "projects,"
"potential," "expects," "plans," "anticipates," "intends,"
"continues," "forecast," "designed," "goal" or the negative of
those words or other comparable words to be uncertain and
forward-looking. Such forward-looking statements include
statements that express plans, anticipation, intent, contingency,
goals, targets, future development and are otherwise not statements
of historical fact. These statements are based on our current
expectations and are subject to risks and uncertainties that could
cause actual results or developments to be materially different
from historical results or from any future results expressed or
implied by such forward-looking statements. Factors that may cause
actual results or developments to differ materially include, but
not limited to: the risks associated with the adequacy of our
existing cash resources and our ability to continue as a going
concern; [the risks associated with our ability to continue to meet
our obligations under our existing debt agreements][?]; the risk
that clinical trials for bertilimumab or AmiKet™ will not be
successful; the risk that bertilimumab, AmiKet™ or compounds
arising from our NanomAb® program will not receive regulatory
approval or achieve significant commercial success; the risk that
we will not be able to find a partner to help conduct the Phase III
trials for AmiKet™ on attractive terms, on a timely basis or at
all; the risk that our other product candidates that appeared
promising in early research and clinical trials do not demonstrate
safety and/or efficacy in larger-scale or later-stage clinical
trials; the risk that we will not obtain approval to market any of
our product candidates; the risks associated with dependence upon
key personnel; the risks associated with reliance on collaborative
partners and others for further clinical trials, development,
manufacturing and commercialization of our product candidates; the
cost, delays and uncertainties associated with our scientific
research, product development, clinical trials and regulatory
approval process; our history of operating losses since our
inception; the highly competitive nature of our business; risks
associated with litigation; and risks associated with our ability
to protect our intellectual property. These factors and other
material risks are more fully discussed in our periodic reports,
including our reports on Forms 8-K, 10-Q and 10-K and other filings
with the U.S. Securities and Exchange Commission. You are urged to
carefully review and consider the disclosures found in our filings
which are available at www.sec.gov or at
www.immunepharmaceuticals.com. You are cautioned not to place undue
reliance on any forward-looking statements, any of which could turn
out to be wrong due to inaccurate assumptions, unknown risks or
uncertainties or other risk factors. We expressly disclaim any
obligation to publicly update any forward looking statements
contained herein, whether as a result of new information, future
events or otherwise, except as required by law.
SOURCE Immune Pharmaceuticals Inc.